| Range: | 1.64-5.34 | Vol Avg: | 8583175 | Last Div: | 0 | Changes: | 0.05 |
| Beta: | 0.52 | Cap: | 2.46B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jul 31 1996 | Empoloyees: | 141 | ||
| CUSIP: | 374163103 | CIK: | 0000886744 | ISIN: | US3741631036 | Country: | US |
| CEO: | Dr. John A. Scarlett M.D. | Website: | https://www.geron.com | ||||
GERN 4.06 Stock Price Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Stock Details
Positive 0.26
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage...
businesswire.com·Thu Nov 21 2024
Positive 0.47
Geron: A Strong Launch And Financial Deals Make It Attractive
Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and s...
seekingalpha.com·Thu Nov 21 2024
Positive 0.18
Geron to Participate in the Stifel 2024 Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage...
businesswire.com·Mon Nov 11 2024
Neutral 0.06
Geron: A Post Earnings And Funding Announcement Assessment
Geron Corporation's imetelstat, now branded as Rytelo, was finally approved by the FDA in ...
seekingalpha.com·Thu Nov 07 2024
Neutral 0.00
Geron Corporation (GERN) Q3 2024 Earnings Call Transcript
Geron Corporation (NASDAQ:GERN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ...
seekingalpha.com·Thu Nov 07 2024
Negative -0.27
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus ...
zacks.com·Thu Nov 07 2024
Neutral 0.00
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announ...
globenewswire.com·Thu Nov 07 2024
Positive 0.26
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage...
businesswire.com·Thu Oct 17 2024
Positive 0.23
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage...
businesswire.com·Tue Oct 15 2024
Positive 0.17
Geron: Derisked And Highly Attractive After Approval
Geron's imetelstat (Rytelo) received FDA approval for MDS, marking a significant milestone...
seekingalpha.com·Mon Sep 23 2024
Positive 0.26
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage...
businesswire.com·Thu Sep 19 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow